

Product Information Sheet for HRP-20081

Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) p17 Protein (produced *in vitro*)

Catalog No. HRP-20081

For research use only. Not for use in humans.

Contributor:

Jaisri Lingappa, M.D., Ph.D., Professor, Department of Global Health, University of Washington, Seattle, Washington, USA

Manufacturer:

Capricorn Products LLC, Portland, Maine, USA

Product Description:

Antibody Class: IgG1

Monoclonal antibody (mAb) prepared against the Gag matrix (MA) protein p17 of human immunodeficiency virus type 1 (HIV-1) was produced from a mouse hybridoma and purified.^{1,2} This anti-HIV-1 p17 mAb recognizes HIV Gag p17^{MA}.¹

Material Provided:

Each vial of HRP-20081 contains approximately 50 μ L of purified mAb in phosphate-buffered saline (PBS; pH \sim 7.0) with 0.04% sodium azide as a preservative. The concentration, expressed as milligrams per milliliter, is shown on the Certificate of Analysis. Note: Lot 70047197 is past the manufacturer's expiration date; however, the contributor has indicated that this mAb is likely to work well in the applications listed in the Functional Activity section.

Packaging/Storage:

HRP-20081 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

HRP-20081 is specific to the Gag MA p17 protein of HIV-1. No cross reactivity with HIV-2, HTLV-I or HTLV-II has been reported. It is recommended to use this mAb at 1:1000 to 1:5000 with anti-mouse IgG1 as a secondary antibody. For electron microscopy (EM), use at 1:60 or 1:70 dilution, then 1:1 with antibody buffer. This mAb labels very well by EM immunogold labeling.¹ Suggested applications are Western blot, immunocytochemistry and immunohistochemistry analysis.¹

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH HIV Reagent Program, NIAID, NIH: Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) p17 Protein (produced *in vitro*), HRP-20081, contributed by Dr. Jaisri Lingappa."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at www.hivreagentprogram.org.

While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- 1. Lingappa, J., Personal Communication.
- Tanaka, M., et al. "Mutations of Conserved Residues in the Major Homology Region Arrest Assembling HIV-1 Gag as a Membrane-Targeted Intermediate Containing Genomic RNA and Cellular Proteins." <u>J. Virol.</u> 90 (2015): 1944-1963. PubMed: 26656702.

ATCC® is a trademark of the American Type Culture Collection.



NIH HIV Reagent Program

www.hivreagentprogram.org

E-mail: contact@HIVReagentProgram.org
Tel: 888-487-0727 | Fax: 703-365-2898